Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

CFTC’s Derivative Rulemaking Under Dodd-Frank Will Extend Into 2012

Publications

September 12, 2011

Title VII of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the "Dodd-Frank Act") establishes a new regulatory scheme for the over-the-counter derivatives market. As we explained in a prior Alert, this summer, the Securities and Exchange Commission ("SEC") and the Commodity Futures Trading Commission ("CFTC") delayed the compliance deadline for many of the provisions of Title VII. At that time, the effective date was fast approaching, but the agencies had not completed required rulemaking related to the new derivatives regulations. While the SEC’s compliance extension was tied to the completion of applicable rulemaking, the CFTC’s extension was set to expire on December 31, 2011.

On September 8, 2011, the CFTC held an open meeting to discuss proposed rules extending the deadline for swap dealers and major swap participants to comply with new swap clearing and trading, swap dealer documentation, and margining requirements. During the meeting, Chairman Gary Gensler made it clear that the CFTC would not complete its Title VII rulemaking by the extended compliance deadline of December 31, 2011, stating "Let me start by saying that we are focused on considering these rules thoughtfully – not against a clock." Gensler then set forth a tentative timeline for the CFTC to consider derivatives rules, which contained a significant number of items in the first quarter of 2012. Additionally, Gensler stated, "[m]uch like we did on July 14, this fall we also will consider further exemptive relief from the application of Dodd-Frank's Title VII requirements."

It now appears clear that it will be well into 2012 before the CFTC completes all rulemaking under Title VII of the Dodd-Frank Act. In the meantime, the CFTC is likely to provide additional extensions and exemptions on compliance. We will continue to monitor both the SEC’s and the CFTC’s rulemaking under Title VII and provide updates as appropriate.


1  Gary Gensler, Chairman, Commodity Futures Trading Commission, Opening Statement, Meeting of the Commodity Futures Trading Commission (Sept. 8, 2011), available here.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.